Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2006

Open Access 01-12-2006 | Review

Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas

Authors: Xiao-Feng Sun, Hong Zhang

Published in: Molecular Cancer | Issue 1/2006

Login to get access

Abstract

Cancer research has mainly focused on alterations of genes and proteins in cancer cells themselves that result in either gain-of-function in oncogenes or loss-of-function in tumour-suppressor genes. However, stromal variables within or around tumours, including blood and lymph vessels, stromal cells and various proteins, have also important impacts on tumour development and progression. It has been shown that disruption of stromal-epithelial interactions influences cellular proliferation, differentiation, death, motility, genomic integrity, angiogenesis, and other phenotypes in various tissues. Moreover, stromal variables are also critical to therapy in cancer patients. In this review, we mainly focus on the clinicopathological significance of stromal variables including angiogenesis, lymphangiogenesis, inflammatory infiltration, matrix metalloproteinase (MMP), and the particularly interesting new cysteine-histidine rich protein (PINCH) in colorectal cancer (CRC).
Appendix
Available only for authorised users
Literature
1.
Sappino AP, Schurch W, Gabbiani G: Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest. 1990, 63: 144-161.PubMed
2.
3.
Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marme D: Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol. 2005, 16: 558-565. 10.1093/annonc/mdi118PubMedCrossRef
4.
Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006, 24: 217-227. 10.1200/JCO.2005.01.5388PubMedCrossRef
5.
Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL, Lathia CD, Alberts SR: A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12–9566 in combination with etoposide and carboplatin. Anticancer Drugs. 2005, 16: 997-1002. 10.1097/01.cad.0000176504.86551.5cPubMedCrossRef
6.
Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF: A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res. 2003, 9: 1323-1232.PubMed
7.
Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H: A phase I study of oral BMS-275291 a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res. 2004, 10: 1963-1970. 10.1158/1078-0432.CCR-1183-02PubMedCrossRef
8.
Noël A, Gilles C, Bajou K, Devy L, Kebers F, Lewalle JM, Maquoi E, Munaut C, Remacle A, Foidart JM: Emerging roles for proteinases in cancer. Invasion Metastasis. 1997, 17: 221-239.PubMed
9.
Sivridis E, Giatromanolaki A, Koukourakis MI: "Stromatogenesis" and tumor progression. Int J Surg Pathol. 2004, 12: 1-9.PubMedCrossRef
10.
Giatromanolaki A, Sivridis E, Koukourakis MI: Tumour angiogenesis: vascular growth and survival. APMIS. 2004, 112: 431-440. 10.1111/j.1600-0463.2004.apm11207-0804.xPubMedCrossRef
11.
Folkman J: What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990, 82: 4-6.PubMedCrossRef
12.
Yonenaga Y, Mori A, Onodera H, Yasuda S, Oe H, Fujimoto A, Tachibana T, Imamura M: Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology. 2005, 69: 159-166. 10.1159/000087840PubMedCrossRef
13.
Björndahl M: Lymphanginogenesis and lymphatic metastasis. Swedish PhD thesis. 2005, ISBN: 91-7140-562-3..
14.
Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D, O'Dwyer ST, Jayson GC: Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer. 2003, 89: 426-430. 10.1038/sj.bjc.6601145PubMedCentralPubMedCrossRef
15.
Leak LV, Burke JF: Fine structure of the lymphatic capillary and the adjoining connective tissue area. Am J Anat. 1966, 118: 785-809. 10.1002/aja.1001180308PubMedCrossRef
16.
Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, Ahmed A: Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol. 2001, 159: 993-1008.PubMedCentralPubMedCrossRef
17.
Bergsland EK: Vascular endothelial growth factor as a therapeutic target in cancer. Am J Health Syst Pharm. 2004, 61: S4-11.PubMed
18.
Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, Alitalo K: Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001, 20: 4762-4773. 10.1093/emboj/20.17.4762PubMedCentralPubMedCrossRef
19.
George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, Swift RI: VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 2001, 3: 420-427. 10.1038/sj.neo.7900186PubMedCentralPubMedCrossRef
20.
Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB: The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol. 2003, 200: 183-189. 10.1002/path.1339PubMedCrossRef
21.
Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K: Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci. 2004, 95: 32-39. 10.1111/j.1349-7006.2004.tb03167.xPubMedCrossRef
22.
Parr C, Jiang WG: Quantitative analysis of lymphangiogenic markers in human colorectal cancer. Int J Oncol. 2003, 23: 533-539.PubMed
23.
Witmer AN, van Blijswijk BC, Dai J, Hofman P, Partanen TA, Vrensen GF, Schlingemann RO: VEGFR-3 in adult angiogenesis. J Pathol. 2001, 195: 490-497. 10.1002/path.969PubMedCrossRef
24.
White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J, Murray JC: Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 2002, 62: 1669-1675.PubMed
25.
Kern A, Taubert H, Scheele J, Rudroff C, Mothes H, Kappler M, Bartel F, Richter KK: Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases. Int J Oncol. 2002, 21: 243-249.PubMed
26.
Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995, 55: 3964-3968.PubMed
27.
Wendum D, Boelle PY, Rigau V, Sebbagh N, Olschwang S, Mourra N, Parc R, Trugnan G, Masliah J, Flejou JF: Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression. Virchows Arch. 2003, 442: 111-117.PubMed
28.
Furudoi A, Tanaka S, Haruma K, Kitadai Y, Yoshihara M, Chayama K, Shimamoto F: Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2002, 62: 157-166. 10.1159/000048262PubMedCrossRef
29.
Bossi P, Viale G, Lee AK, Alfano R, Coggi G, Bosari S: Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res. 1995, 55: 5049-5053.PubMed
30.
Fox SH, Whalen GF, Sanders MM, Burleson JA, Jennings K, Kurtzman S, Kreutzer D: Angiogenesis in normal tissue adjacent to colon cancer. J Surg Oncol. 1998, 69: 230-234. 10.1002/(SICI)1096-9098(199812)69:4<230::AID-JSO7>3.0.CO;2-QPubMedCrossRef
31.
Rmali KA, Puntis MC, Jiang WG: Prognostic values of tumor endothelial markers in patients with colorectal cancer. World J Gastroenterol. 2005, 11: 1283-1286.PubMedCentralPubMedCrossRef
32.
Kondo Y, Arii S, Furutani M, Isigami S, Mori A, Onodera H, Chiba T, Imamura M: Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer. 2000, 88: 1820-1827. 10.1002/(SICI)1097-0142(20000415)88:8<1820::AID-CNCR10>3.0.CO;2-5PubMedCrossRef
33.
Sharma RA, Dalgleish AG, Steward WP, O'Byrne KJ: Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). Oncol Rep. 2003, 10: 1625-1631.PubMed
34.
Choi HJ, Hyun MS, Jung GJ, Kim SS, Hong SH: Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology. 1998, 55: 575-581. 10.1159/000011915PubMedCrossRef
35.
Onogawa S, Tanaka S, Oka S, Morihara M, Kitadai Y, Sumii M, Yoshihara M, Shimamoto F, Haruma K, Chayama K: Clinical significance of angiogenesis in rectal carcinoid tumors. Oncol Rep. 2002, 9: 489-494.PubMed
36.
Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T: Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer. 1996, 78: 226-231. 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-JPubMedCrossRef
37.
Vermeulen PB, Van den Eynden GG, Huget P, Goovaerts G, Weyler J, Lardon F, Van Marck E, Hubens G, Dirix LY: Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer. 1999, 79: 316-322.PubMedCentralPubMedCrossRef
38.
Acikalin MF, Oner U, Topcu I, Yasar B, Kiper H, Colak E: Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig Liver Dis. 2005, 37: 162-169. 10.1016/j.dld.2004.09.028PubMedCrossRef
39.
Engel CJ, Bennett ST, Chambers AF, Doig GS, Kerkvliet N, O'Malley FP: Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol. 1996, 20: 1260-1265. 10.1097/00000478-199610000-00012PubMedCrossRef
40.
Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB: Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg. 1995, 222: 695-699.PubMedCentralPubMedCrossRef
41.
Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL, Tumour and Angiogenesis Research Group: Tumour and Angiogenesis Research Group. Inclusion of vasculature-related variables in the Dukes staging system of colon cancer. Clin Cancer Res. 2005, 11: 8653-8660. 10.1158/1078-0432.CCR-05-1464PubMedCrossRef
42.
Giatromanolaki A, Stathopoulos GP, Tsiobanou E, Papadimitriou C, Georgoulias V, Gatter KC, Harris AL, Koukourakis MI: Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer. 1999, 86: 1421-1430. 10.1002/(SICI)1097-0142(19991015)86:8<1421::AID-CNCR6>3.0.CO;2-XPubMedCrossRef
43.
Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer. 2003, 88: 1424-1431. 10.1038/sj.bjc.6600874PubMedCentralPubMedCrossRef
44.
Lackner C, Jukic Z, Tsybrovskyy O, Jatzko G, Wette V, Hoefler G, Klimpfinger M, Denk H, Zatloukal K: Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch. 2004, 445: 160-167. 10.1007/s00428-004-1051-zPubMedCrossRef
45.
Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002, 160: 985-1000.PubMedCentralPubMedCrossRef
46.
Witmer AN, van Blijswijk BC, van Noorden CJ, Vrensen GF, Schlingemann RO: In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. J Histochem Cytochem. 2004, 52: 39-52.PubMedCrossRef
47.
Galindo-Gallego M, Fernandez Acenero MJ, Sanz Ortega J, Aljama A: Vascular enumeration as a prognosticator for colorectal carcinoma. Eur J Cancer. 2000, 36: 55-60. 10.1016/S0959-8049(99)00243-9PubMedCrossRef
48.
Gunther K, Radkow T, Reymond MA, Pfluger R, Dimmler A, Hohenberger W, Papadopoulos T: Angiogenesis and dendritic cell density are not correlated with metachronous distant metastasis in curatively operated rectal cancer. Int J Colorectal Dis. 2003, 18: 300-308.PubMed
49.
Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000, 6: 4064-4068.PubMed
50.
Cianchi F, Messerini L, Palomba A, Boddi V, Perigli G, Pucciani F, Bechi P, Cortesini C: Character of the invasive margin in colorectal cancer: does it improve prognostic information of Dukes staging?. Dis Colon Rectum. 1997, 40: 1170-1175. 10.1007/BF02055162PubMedCrossRef
51.
Banner BF, Whitehouse R, Baker SP, Swanson RS: Tumor angiogenesis in stage II colorectal carcinoma: association with survival. Am J Clin Pathol. 1998, 109: 733-737.PubMed
52.
Galindo-Gallego M, Fernandez-Acenero MJ, Sanz-Ortega J, Aljama A, Lopez-Elzaurdia C: Prognostic significance of microvascular counts in rectal carcinoma. Pathol Res Pract. 2000, 196: 607-612.PubMedCrossRef
53.
Tarta C, Teixeira CR, Tanaka S, Haruma K, Chiele-Neto C, da Silva VD: Angiogenesis in advanced colorectal adenocarcinoma with special reference to tumoral invasion. Arq Gastroenterol. 2002, 39: 32-38. 10.1590/S0004-28032002000100007PubMedCrossRef
54.
Shan YS, Lee JC, Chow NH, Yang HB, Wang ST: Immunohistochemical microvessel count is not a reliable prognostic predictor in colorectal carcinoma. Hepatogastroenterology. 2003, 50: 1316-1320.PubMed
55.
Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM: Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003, 97: 960-968. 10.1002/cncr.11152PubMedCrossRef
56.
Peeters CF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Ruers TJ: Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients. Int J Cancer. 2004, 112: 554-559. 10.1002/ijc.20374PubMedCrossRef
57.
O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the uppression of metastases by a Lewis lung carcinoma. Cell. 1994, 79: 315-328. 10.1016/0092-8674(94)90200-3PubMedCrossRef
58.
Kockar C, Kockar O, Ozturk M, Dagli M, Bavbek N, Kosar A: Global fibrinolytic capacity increased exponentially in metastatic colorectal cancer. Clin Appl Thrombosis/Hemostasis. 2005, 11: 227-230. 10.1177/107602960501100214.CrossRef
59.
Oya M, Akiyama Y, Yanagida T, Akao S, Ishikawa H: Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today. 1998, 28: 373-378. 10.1007/s005950050144PubMedCrossRef
60.
Oya M, Akiyama Y, Okuyama T, Ishikawa H: High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001, 31: 388-394. 10.1093/jjco/hye075PubMedCrossRef
61.
Caine GJ, Stonelake PS, Lip GY, Kehoe ST: The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002, 4: 465-473. 10.1038/sj.neo.7900263PubMedCentralPubMedCrossRef
62.
Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV: Vascular endothelial growth factor messenger rna expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res. 2006, 12: 29-33. 10.1158/1078-0432.CCR-05-1275PubMedCrossRef
63.
Akagi K, Ikeda Y, Miyazaki M, Abe T, Kinoshita J, Maehara Y, Sugimachi K: Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer. 2000, 83: 887-891. 10.1054/bjoc.2000.1396PubMedCentralPubMedCrossRef
64.
Kaio E, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K, Chayama K: Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2003, 64: 61-73. 10.1159/000066511PubMedCrossRef
65.
Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F, Barone C: Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer. 1998, 78: 765-770.PubMedCentralPubMedCrossRef
66.
Ono T, Miki C: Factors influencing tissue concentration of vascular endothelial growth factor in colorectal carcinoma. Am J Gastroenterol. 2000, 95: 1062-1067. 10.1111/j.1572-0241.2000.01909.xPubMedCrossRef
67.
Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N, Nakamura M: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer. 1998, 77: 998-1002.PubMedCentralPubMedCrossRef
68.
Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, Muretto P, Catalano G: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000, 6: 2803-2807.PubMed
69.
Wang TB, Huang YH, Lan P, Song XM, Wang JP: Correlation of lymphangiogenesis to progression of colorectal cancer. Ai Zheng. 2005, 24: 1276-1279.PubMed
70.
Byrne AM, Bouchier-Hayes DJ, Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005, 9: 777-794.PubMedCrossRef
71.
Robinson CJ, Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001, 114: 853-865.PubMed
72.
Cheung N, Wong MP, Yuen ST, Leung SY, Chung LP: Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol. 1998, 29: 910-914. 10.1016/S0046-8177(98)90195-2PubMedCrossRef
73.
Okamoto K, Oshika Y, Fukushima Y, Ohnishi Y, Tokunaga T, Tomii Y, Kijima H, Yamazaki H, Ueyama Y, Tamaoki N, Nakumura M: Xenografts of human solid tumors frequently express cellular-associated isoform of vascular endothelial growth factor (VEGF) 189. Oncol Rep. 1999, 6: 1201-1204.PubMed
74.
Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ: VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002, 62: 4123-4131.PubMed
75.
Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO: VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004, 64: 7822-7835. 10.1158/0008-5472.CAN-04-0934PubMedCrossRef
76.
Fogt F, Zimmerman RL, Ross HM, Daly T, Gausas RE: Identification of lymphatic vessels in malignant, adenomatous and normal colonic mucosa using the novel immunostain D2–40. Oncol Rep. 2004, 11: 47-50.PubMed
77.
Kuroyama S, Kobayashi N, Ohbu M, Ohtani Y, Okayasu I, Kakita A: Enzyme histochemical analysis of lymphatic vessels in colon carcinoma: occurrence of lymphangiogenesis within the tumor. Hepatogastroenterology. 2005, 52: 1057-1061.PubMed
78.
Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002, 296: 1883-1886. 10.1126/science.1071420PubMedCrossRef
79.
Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001, 7: 192-198. 10.1038/84643PubMedCrossRef
80.
Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001, 7: 186-191. 10.1038/84635PubMedCrossRef
81.
Medzhitov R, Janeway C: Innate immunity. N Engl J Med. 2000, 343: 338-344. 10.1056/NEJM200008033430506PubMedCrossRef
82.
Benjamini E, Wan AM, Langton BC, Andria ML: Cell activation and immunogenicity. Dev Biol Stand. 1986, 63: 29-39.PubMed
83.
Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G: Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol. 2003, 46: 33-57.PubMedCrossRef
84.
Fossum B, Gedde-Dahl T, Breivik J, Eriksen JA, Spurkland A, Thorsby E, Gaudernack G: p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly – >Asp). Int J Cancer. 1994, 56: 40-45.PubMedCrossRef
85.
Maeta M, Saito H, Kondo A, Yamashiro H, Tsujitani S, Ikeguchi M, Kaibara N: Effects of super-extended paraaortic lymphadenectomy (PAL) on biological responses in totally gastrectomized patients with T3 or T4 gastric cancer. Gastric Cancer. 1998, 1: 57-63. 10.1007/s101200050055PubMedCrossRef
86.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 357: 539-545. 10.1016/S0140-6736(00)04046-0PubMedCrossRef
87.
Henry F, Bretaudeau L, Barbieux I, Meflah K, Gregoire M: Induction of antigen presentation by macrophages after phagocytosis of tumour apoptotic cells. Res Immunol. 1998, 149: 673-679. 10.1016/S0923-2494(99)80037-6PubMedCrossRef
88.
Kaattari S, Scibienski RJ, Benjamini E: The immunoregulatory role of antigen-antibody complexes. I. Assessment of B and T-cell responses. Immunology. 1980, 40: 9-16.PubMedCentralPubMed
89.
Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, Tuppurainen K, Makela J, Karttunen TJ, Makinen MJ: Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005, 41: 2645-2654. 10.1016/j.ejca.2005.07.017PubMedCrossRef
90.
Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol. 2000, 18: I767-811. 10.1146/annurev.immunol.18.1.767.CrossRef
91.
Dabbous MK, North SM, Haney L, Tipton DA, Nicolson GL: Effects of mast cell-macrophage interactions on the production of collagenolytic enzymes by metastatic tumor cells and tumor-derived and stromal fibroblasts. Clin Exp Metastasis. 1995, 13: 33-41. 10.1007/BF00144016PubMedCrossRef
92.
Dimitriadou V, Koutsilieris M: Mast cell-tumor cell interactions: for or against tumour growth and metastasis?. Anticancer Res. 1997, 17: 1541-1549.PubMed
93.
94.
Etoh T, Shibuta K, Barnard GF, Kitano S, Mori M: Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res. 2000, 6: 3545-3551.PubMed
95.
Adachi Y, Mori M, Kuroiwa S, Sugimachi K, Enjoji M: Histopathological evaluation of survival time in patients with colorectal carcinoma. J Surg Oncol. 1989, 42: 219-224.PubMedCrossRef
96.
Ali AA, McMillan DC, Matalka II, McNicol AM, McArdle CS: Tumour T-lymphocyte subset infiltration and tumour recurrence following curative resection for colorectal cancer. Eur J Surg Oncol. 2004, 30: 292-295. 10.1016/j.ejso.2003.11.018PubMedCrossRef
97.
Canna K, McArdle PA, McMillan DC, McKee RF, McNicol AM, Horgan PG, McArdle CS: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005, 92: 651-654. 10.1038/sj.bjc.6602419PubMedCentralPubMedCrossRef
98.
Carlon CA, Fabris G, Arslan-Pagnini C, Pluchinotta AM, Chinelli E, Carniato S: Prognostic correlations of operable carcinoma of the rectum. Dis Colon Rectum. 1985, 28: 47-50.PubMedCrossRef
99.
Di Giorgio A, Botti C, Tocchi A, Mingazzini P, Flammia M: The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients. Int Surg. 1992, 77: 256-260.PubMed
100.
Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE: Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep. 2003, 10: 309-313.PubMed
101.
Harrison JC, Dean PJ, el-Zeky F, Vander Zwaag R: From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol. 1994, 25: 498-505. 10.1016/0046-8177(94)90122-8PubMedCrossRef
102.
Murray D, Hreno A, Dutton J, Hampson LG: Prognosis in colon cancer: a pathologic reassessment. Arch Surg. 1975, 110: 908-913.PubMedCrossRef
103.
Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, van Krieken JH: Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect – a histopathological and immunohistochemical study. BMC Cancer. 2001, 1: 7- 10.1186/1471-2407-1-7PubMedCentralPubMedCrossRef
104.
Spratt JS, Spjut HJ: Prevalence and prognosis of individual clinical and pathologic variables associated with colorectal carcinoma. Cancer. 1967, 20: 1976-1985. 10.1002/1097-0142(196711)20:11<1976::AID-CNCR2820201125>3.0.CO;2-MPubMedCrossRef
105.
106.
Zhou XG, Yu BM, Shen YX: Surgical treatment and late results in 1226 cases of colorectal cancer. Dis Colon Rectum. 1983, 26: 250-256.PubMedCrossRef
107.
Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997, 79: 2320-2328. 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-PPubMedCrossRef
108.
Diez M, Pollan M, Enriquez JM, Dominguez P, Santana A, Tobaruela E, Muguerza JM, Arrieta F, Rodriguez A, Ruiz A: Histopathologic prognostic score in colorectal adenocarcinomas. Anticancer Res. 1998, 18: 689-694.PubMed
109.
Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A: Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer. 2000, 88: 1544-1548. 10.1002/(SICI)1097-0142(20000401)88:7<1544::AID-CNCR7>3.0.CO;2-SPubMedCrossRef
110.
Gao JF, Arbman G, Wadhra TI, Zhang H, Sun XF: Relationships of tumor inflammatory infiltration and necrosis with microsatellite instability in colorectal cancers. World J Gastroenterol. 2005, 11: 2179-2183.PubMedCentralPubMedCrossRef
111.
Kubota Y, Petras RE, Easley KA, Bauer TW, Tubbs RR, Fazio VW: Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer. 1992, 70: 2602-2609. 10.1002/1097-0142(19921201)70:11<2602::AID-CNCR2820701106>3.0.CO;2-WPubMedCrossRef
112.
113.
Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE: Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17–1A. Int J Cancer. 2003, 105: 717-723. 10.1002/ijc.11139PubMedCrossRef
114.
Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, Fleuren GJ, Kuppen PJ: Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest. 2004, 84: 493-501. 10.1038/labinvest.3700055PubMedCrossRef
115.
Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F: Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. 1999, 189: 487-495. 10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-IPubMedCrossRef
116.
Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM: Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997, 182: 318-324. 10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6PubMedCrossRef
117.
Watt AG, House AK: Colonic carcinoma: a quantitative assessment of lymphocyte infiltration at the periphery of colonic tumors related to prognosis. Cancer. 1978, 41: 279-282. 10.1002/1097-0142(197801)41:1<279::AID-CNCR2820410139>3.0.CO;2-BPubMedCrossRef
118.
Cianchi F, Palomba A, Messerini L, Boddi V, Asirelli G, Perigli G, Bechi P, Taddei A, Pucciani F, Cortesini C: Tumor angiogenesis in lymph node-negative rectal cancer: correlation with clinicopathological parameters and prognosis. Ann Surg Oncol. 2002, 9: 20-26. 10.1245/aso.2002.9.1.20PubMedCrossRef
119.
Fujita S, Shimoda T, Yoshimura K, Yamamoto S, Akasu T, Moriya Y: Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol. 2003, 84: 127-131. 10.1002/jso.10308PubMedCrossRef
120.
Wallin Å, Svanvik J, Adell G, Sun XF: Expression of PRL proteins at the margin of rectal cancers in relation to preoperative radiotherapy. Int J Radiat Oncol Biol Phys. .
121.
Dundas SA, Laing RW, O'Cathain A, Seddon I, Slater DN, Stephenson TJ, Underwood JC: Feasibility of new prognostic classification for rectal cancer. J Clin Pathol. 1988, 41: 1273-1276.PubMedCentralPubMedCrossRef
122.
Ohtani H, Naito Y, Saito K, Nagura H: Expression of costimulatory molecules B7–1 and B7–2 by macrophages along invasive margin of colon cancer: a possible antitumor immunity?. Lab Invest. 1997, 77: 231-241.PubMed
123.
Sugita J, Ohtani H, Mizoi T, Saito K, Shiiba K, Sasaki I, Matsuno S, Yagita H, Miyazawa M, Nagura H: Close Association between Fas Ligand (FasL; CD95L)-positive Tumor-associated Macrophages and Apoptotic Cancer Cells along Invasive Margin of Colorectal Carcinoma: A Proposal on Tumor-Host Interactions. Jpn J Cancer Res. 2002, 93: 320-328.PubMedCrossRef
124.
Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y, Zhao LJ: Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol. 2005, 11: 1210-1214.PubMedCentralPubMedCrossRef
125.
Oberg A, Samii S, Stenling R, Lindmark G: Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis. 2002, 17: 25-29. 10.1007/s003840100337PubMedCrossRef
126.
Miyagawa S, Miwa S, Soeda J, Kobayashi A, Kawasaki S: Morphometric analysis of liver macrophages in patients with colorectal liver metastasis. Clin Exp Metastasis. 2002, 19: 119-125. 10.1023/A:1014571013978PubMedCrossRef
127.
Nakayama Y, Nagashima N, Minagawa N, Inoue Y, Katsuki T, Onitsuka K, Sako T, Hirata K, Nagata N, Itoh H: Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res. 2002, 22: 4291-6429.PubMed
128.
Della Porta M, Danova M, Rigolin GM, Brugnatelli S, Rovati B, Tronconi C, Fraulini C, Russo Rossi A, Riccardi A, Castoldi G: Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology. 2005, 68: 276-284. 10.1159/000086784PubMedCrossRef
129.
Banner BF, Sonmez-Alpan E, Yousem SA: An immunophenotypic study of the inflammatory cell populations in colon adenomas and carcinomas. Mod Pathol. 1993, 6: 295-301.PubMed
130.
Schwaab T, Weiss JE, Schned AR, Barth RJ: Dendritic cell infiltration in colon cancer. J Immunother. 2001, 24: 130-137. 10.1097/00002371-200103000-00007.CrossRef
131.
Ambe K, Mori M, Enjoji M: S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer. 1989, 63: 496-503. 10.1002/1097-0142(19890201)63:3<496::AID-CNCR2820630318>3.0.CO;2-KPubMedCrossRef
132.
Suzuki A, Masuda A, Nagata H, Kameoka S, Kikawada Y, Yamakawa M, Kasajima T: Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J Pathol. 2002, 196: 37-43. 10.1002/path.1018PubMedCrossRef
133.
Miyagawa S, Soeda J, Takagi S, Miwa S, Ichikawa E, Noike T: Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol. 2004, 35: 1392-1396. 10.1016/j.humpath.2004.07.018PubMedCrossRef
134.
Dadabayev AR, Sandel MH, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn C, Ensink NG, Tollenaar RA, van de Velde CJ, Kuppen PJ: Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol Immunother. 2004, 53: 978-986. 10.1007/s00262-004-0548-2PubMedCrossRef
135.
Lissoni P, Malugani F, Bonfanti A, Bucovec R, Secondino S, Brivio F, Ferrari-Bravo A, Ferrante R, Vigore L, Rovelli F, Mandala M, Viviani S, Fumagalli L, Gardani GS: Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents. 2001, 15: 140-144.PubMed
136.
Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996, 2: 1096-1103. 10.1038/nm1096-1096PubMedCrossRef
137.
Inoue Y, Nakayama Y, Minagawa N, Katsuki T, Nagashima N, Matsumoto K, Shibao K, Tsurudome Y, Hirata K, Nagata N, Itoh H: Relationship between interleukin-12-expressing cells and antigen-presenting cells in patients with colorectal cancer. Anticancer Res. 2005, 25: 3541-3546.PubMed
138.
Nakayama Y, Inoue Y, Minagawa N, Katsuki T, Nagashima N, Onitsuka K, Tsurudome Y, Sako T, Hirata K, Nagata N, Itoh H: Relationships between S-100 protein-positive cells and clinicopathological factors in patients with colorectal cancer. Anticancer Res. 2003, 23: 4423-4426.PubMed
139.
Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn CM, Ensink NG, Tollenaar RA, van de Velde CJ, Kuppen PJ: Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res. 2005, 11: 2576-2582. 10.1158/1078-0432.CCR-04-1448PubMedCrossRef
140.
Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992, 69: 11-25. 10.1016/0092-8674(92)90115-SPubMedCrossRef
141.
Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino M, Goicoechea S, McDonald JA, Dedhar S: Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem. 1998, 273: 528-536. 10.1074/jbc.273.1.528PubMedCrossRef
142.
Tan C, Costello P, Sanghera J, Dominguez D, Baulida J, de Herreros AG, Dedhar S: Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells. Oncogene. 2001, 20: 133-140. 10.1038/sj.onc.1204052PubMedCrossRef
143.
Burridge K, Chrzanowska-Wodnicka M: Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol. 1996, 12: 463-518. 10.1146/annurev.cellbio.12.1.463PubMedCrossRef
144.
Varani J: Interaction of tumor cells with the extracellular matrix. Revis Biol Celular. 1987, 12: 1-113.PubMed
145.
Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T: Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003, 253: 269-285. 10.1023/A:1026028303196PubMedCrossRef
146.
Momohara S, Okamoto H, Komiya K, Ikari K, Takeuchi M, Tomatsu T, Kamatani N: Matrix metalloproteinase 28/epilysin expression in cartilage from patients with rheumatoid arthritis and osteoarthritis: comment on the article by Kevorkian et al. Arthritis Rheum. 2004, 50: 131-141. 10.1002/art.20799CrossRef
147.
Stetler-Stevenson WG, Hewitt R, Corcoran M: Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol. 1996, 7: 147-154. 10.1006/scbi.1996.0020PubMedCrossRef
148.
Lukashev ME, Werb Z: ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 1998, 8: 437-441. 10.1016/S0962-8924(98)01362-2PubMedCrossRef
149.
Kataoka H, Uchino H, Iwamura T, Seiki M, Nabeshima K, Koono M: Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am J Pathol. 1999, 154: 457-468.PubMedCentralPubMedCrossRef
150.
Gorelik L, Flavell RA: Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001, 7: 1118-1122. 10.1038/nm1001-1118PubMedCrossRef
151.
Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002, 2: 161-174. 10.1038/nrc745PubMedCrossRef
152.
Yamamoto H, Horiuchi S, Adachi Y, Taniguchi H, Nosho K, Min Y, Imai K: Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancer. Carcinogenesis. 2004, 25: 325-332. 10.1093/carcin/bgh011PubMedCrossRef
153.
Ala-aho R, Grenman R, Seth P, Kahari VM: Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene. 2002, 21: 1187-1195. 10.1038/sj.onc.1205198PubMedCrossRef
154.
Sun Y, Cheung JM, Martel-Pelletier J, Pelletier JP, Wenger L, Altman RD, Howell DS, Cheung HS: Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem. 2000, 275: 11327-11332. 10.1074/jbc.275.15.11327PubMedCrossRef
155.
Baker EA, Bergin FG, Leaper DJ: Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg. 2000, 87: 1215-1221. 10.1046/j.1365-2168.2000.01531.xPubMedCrossRef
156.
Behrens P, Mathiak M, Mangold E, Kirdorf S, Wellmann A, Fogt F, Rothe M, Florin A, Wernert N: Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J Cancer. 2003, 107: 183-188. 10.1002/ijc.11336PubMedCrossRef
157.
Chan CC, Menges M, Orzechowski HD, Orendain N, Pistorius G, Feifel G, Zeitz M, Stallmach A: Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. Int J Colorectal Dis. 2001, 16: 133-140. 10.1007/s003840100287PubMedCrossRef
158.
159.
Islekel H, Oktay G, Terzi C, Canda AE, Fuzun M, Kupelioglu A: Matrix metalloproteinase-9, -3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct. 2006, .
160.
Karakiulakis G, Papanikolaou C, Jankovic SM, Aletras A, Papakonstantinou E, Vretou E, Mirtsou-Fidani V: Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis. 1997, 17: 158-168.PubMed
161.
Langenskiold M, Holmdahl L, Falk P, Ivarsson ML: Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis. 2005, 20: 245-252. 10.1007/s00384-004-0667-4PubMedCrossRef
162.
Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F: Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996, 56: 190-196.PubMed
163.
Luo HZ, Zhou ZG, Yang L, Yu YY, Tian C, Zhou B, Zheng XL, Xia QJ, Li Y, Wang R: Clinicopathologic and prognostic significance of MMP-7 (matrilysin) expression in human rectal cancer. Jpn J Clin Oncol. 2005, 35: 739-744. 10.1093/jjco/hyi195PubMedCrossRef
164.
Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ: Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer. 1998, 78: 1495-1502.PubMedCentralPubMedCrossRef
165.
Roeb E, Arndt M, Jansen B, Schumpelick V, Matern S: Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis. 2004, 19: 518-524. 10.1007/s00384-004-0592-6PubMedCrossRef
166.
Saitoh Y, Yanai H, Higaki S, Nohara H, Yoshida T, Okita K: Relationship between matrix metalloproteinase-7 and pit pattern in early stage colorectal cancer. Gastrointest Endosc. 2004, 59: 385-392. 10.1016/S0016-5107(03)02817-7PubMedCrossRef
167.
Zeng ZS, Shu WP, Cohen AM, Guillem JG: Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res. 2002, 8: 144-148.PubMed
168.
Bodey B, Bodey B, Siegel SE, Kaiser HE: Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas. In Vivo. 2000, 14: 659-666.PubMed
169.
Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P, Lopez-Otin C, Saarialho-Kere U: Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig Dis Sci. 2004, 49: 653-661. 10.1023/B:DDAS.0000026314.12474.17PubMedCrossRef
170.
Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 1996, 2: 461-462. 10.1038/nm0496&ndash;461PubMedCrossRef
171.
Ring P, Johansson K, Hoyhtya M, Rubin K, Lindmark G: Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer – a predictor of tumour stage. Br J Cancer. 1997, 76: 805-811.PubMedCentralPubMedCrossRef
172.
Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H: Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res. 1997, 88: 72-81.PubMedCrossRef
173.
Masaki T, Matsuoka H, Sugiyama M, Abe N, Goto A, Sakamoto A, Atomi Y: Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer. 2001, 84: 1317-1321. 10.1054/bjoc.2001.1790PubMedCentralPubMedCrossRef
174.
Ogawa M, Ikeuchi K, Watanabe M, Etoh K, Kobayashi T, Takao Y, Anazawa S, Yamazaki Y: Expression of matrix metalloproteinase 7, laminin and type IV collagen-associated liver metastasis in human colorectal cancer: immunohistochemical approach. Hepatogastroenterology. 2005, 52: 875-880.PubMed
175.
Leeman MF, McKay JA, Murray GI: Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol. 2002, 55: 758-762. 10.1136/jcp.55.10.758PubMedCentralPubMedCrossRef
176.
Patterson BC, Sang QA: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem. 1997, 272: 28823-28825. 10.1074/jbc.272.46.28823PubMedCrossRef
177.
O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA: Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem. 1999, 274: 29568-29571. 10.1074/jbc.274.41.29568PubMedCrossRef
178.
Skoglund J, Emterling A, Arbman G, Anglard P, Sun XF: Clinicopathological significance of stromelysin-3 expression in colorectal cancer. Oncology. 2004, 67: 67-72. 10.1159/000080288PubMedCrossRef
179.
Gao J, Arbman G, Rearden A, Sun XF: Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer. Neoplasia. 2004, 6: 796-801. 10.1593/neo.04304PubMedCentralPubMedCrossRef
180.
Levy A, Zucman J, Delattre O, Mattei MG, Rio MC, Basset P: Assignment of the human stromelysin 3 (STMY3) gene to the q11.2 region of chromosome 22. Genomics. 1992, 13: 881-883. 10.1016/0888-7543(92)90175-RPubMedCrossRef
181.
Anglard P, Melot T, Guerin E, Thomas G, Basset P: Structure and promoter characterization of the human stromelysin-3 gene. J Biol Chem. 1995, 270: 20337-20344. 10.1074/jbc.270.35.20337PubMedCrossRef
182.
Basset P, Wolf C, Chambon P: Expression of the Stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat. 1993, 24: 185-193. 10.1007/BF01833259PubMedCrossRef
183.
Pei D, Weiss SJ: Furin-dependant intracellular activation of the human Stromelysin-3 zymogen. Nature. 1995, 375: 244-247. 10.1038/375244a0PubMedCrossRef
184.
Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001, 17: 463-516. 10.1146/annurev.cellbio.17.1.463PubMedCentralPubMedCrossRef
185.
Manes S, Mira E, Barbacid MM, Cipres A, Fernandez-Resa P, Buesa JM, Merida I, Aracil M, Marquez G, Martinez-A C: Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem. 1997, 272: 25706-25712. 10.1074/jbc.272.41.25706PubMedCrossRef
186.
Boulay A, Masson R, Chenard MP, El Fahime M, Cassard L, Bellocq JP, Sautes-Fridman C, Basset P, Rio MC: High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res. 2001, 61: 2189-2193.PubMed
187.
Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y, Kodama K, Goya M, Chiba T, Ochiai A: Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res. 2004, 64: 665-671. 10.1158/0008-5472.CAN-03-1916PubMedCrossRef
188.
Soni S, Mathur M, Shukla NK, Deo SV, Ralhan R: Stromelysin-3 expression is an early event in human oral tumorigenesis. Int J Cancer. 2003, 107: 309-316. 10.1002/ijc.11366PubMedCrossRef
189.
Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P, Gespach C: Neoplastic progression of human colorectal cancer is associated with over expression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer. 1995, 64: 70-75.PubMedCrossRef
190.
Thewes M, Pohlmann G, Atkinson M, Mueller J, Putz B, Hofler H: Stromelysin-3 (ST3) mRNA expression in colorectal carcinomas. Diagn Mol Pathol. 1996, 5: 284-290. 10.1097/00019606-199612000-00010PubMedCrossRef
191.
Urbanski SJ, Edwards DR, Hershfield N, Huchcroft SA, Shaffer E, Sutherland L, Kossakowska AE: Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia. Diagn Mol Pathol. 1993, 2: 81-89.PubMedCrossRef
192.
Wlodarczyk J, Bethke B, Mueller E, Stolte M, Mueller J: A comparative study of E-cadherin and stromelysin-3 expression in de novo and ex adenoma carcinoma of the colorectum. Virchows Arch. 2001, 439: 756-761.PubMedCrossRef
193.
Rouyer N, Wolf C, Chenard M, Rio MC, Chambon P, Bellocq JP, Basset P: Stromelysin-3 gene expression in human cancer: an overview. Invasion Metastasis. 1995, 14: 1994-269.
194.
Mueller J, Mueller E, Arras E, Bethke B, Stolte M, Hofler H: Stromelysin-3 expression in early (pT1) carcinomas and pseudoinvasive lesions of the colorectum. Virchows Arch. 1997, 430: 213-219. 10.1007/BF01324804PubMedCrossRef
195.
Rearden A: A new LIM protein containing an autoepitope homologous to "senescent cell antigen". Biochem Biophys Res Commun. 1994, 201: 1124-1131. 10.1006/bbrc.1994.1822PubMedCrossRef
196.
Dougherty GW, Chopp T, Qi SM, Cutler ML: The Ras suppressor Rsu-1 binds to the LIM 5 domain of the adaptor protein PINCH1 and participates in adhesion-related functions. Exp Cell Res. 2005, 306: 168-179. 10.1016/j.yexcr.2005.01.025PubMedCrossRef
197.
Tu Y, Li F, Wu C: Nck-2, a novel Src homology2/3-containing adaptor protein that interacts with the LIM-only protein PINCH and components of growth factor receptor kinase-signaling pathways. Mol Biol Cell. 1998, 9: 3367-3382.PubMedCentralPubMedCrossRef
198.
Tu Y, Li F, Goicoechea S, Wu C: The LIM-only protein PINCH directly interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading cells. Mol Cell Biol. 1999, 19: 2425-2434.PubMedCentralPubMedCrossRef
199.
Hobert O, Moerman DG, Clark KA, Beckerle MC, Ruvkun G: A conserved LIM protein that affects muscular adherens junction integrity and mechanosensory function in Caenorhabditis elegans. J Cell Biol. 1999, 144: 45-57. 10.1083/jcb.144.1.45PubMedCentralPubMedCrossRef
200.
Braun A, Bordoy R, Stanchi F, Moser M, Kostka GG, Ehler E, Brandau O, Fassler R: PINCH2 is a new five LIM domain protein, homologous to PINCHand localized to focal adhesions. Exp Cell Res. 2003, 284: 239-250. 10.1016/S0014-4827(02)00039-3PubMedCrossRef
201.
Dawid IB, Breen JJ, Toyama R: LIM domains: multiple roles as adapters and functional modifiers in protein interactions. Trends Genet. 1998, 14: 156-162. 10.1016/S0168-9525(98)01424-3PubMedCrossRef
202.
Jurata LW, Gill GN: Structure and function of LIM domains. Curr Top Microbiol Immunol. 1998, 228: 75-113.PubMed
203.
Tu Y, Huang Y, Zhang Y, Hua Y, Wu C: A new focal adhesion protein that interacts with integrin-linked kinase and regulates cell adhesion and spreading. J Cell Biol. 2001, 153: 585-598. 10.1083/jcb.153.3.585PubMedCentralPubMedCrossRef
204.
Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC, Dedhar S: Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature. 1996, 379: 91-96. 10.1038/379091a0PubMedCrossRef
205.
Yamaji S, Suzuki A, Sugiyama Y, Koide Y, Yoshida M, Kanamori H, Mohri H, Ohno S, Ishigatsubo Y: A novel integrin-linked kinase-binding protein, affixin, is involved in the early stage of cell-substrate interaction. J Cell Biol. 2001, 153: 1251-164. 10.1083/jcb.153.6.1251PubMedCentralPubMedCrossRef
206.
Zhang Y, Chen K, Tu Y, Wu C: Distinct roles of two structurally closely related focal adhesion proteins, alpha-parvins and beta-parvins, in regulation of cell morphology and survival. J Biol Chem. 2004, 279: 41695-41705. 10.1074/jbc.M401563200PubMedCrossRef
207.
Turner CE, Glenney JR, Burridge K: Paxillin. a new vinculin-binding protein present in focal adhesions. J Cell Biol. 1990, 111: 1059-1068. 10.1083/jcb.111.3.1059PubMedCrossRef
208.
Zhang Y, Chen K, Guo L, Wu C: Characterization of PINCH-2, a new focal adhesion protein that regulates the PINCH-1-ILK interaction, cell spreading, and migration. J Biol Chem. 2002, 277: 38328-38338. 10.1074/jbc.M205576200PubMedCrossRef
209.
Zhang Y, Guo L, Chen K, Wu C: A critical role of the PINCH-integrin-linked kinase interaction in the regulation of cell shape change and migration. J Biol Chem. 2002, 277: 318-326. 10.1074/jbc.M108257200PubMedCrossRef
210.
Guo L, Wu C: Regulation of fibronectin matrix deposition and cell proliferation by the PINCH-ILK-CH-ILKBP complex. FASEB J. 2002, 16: 1298-1300.PubMed
211.
Wang-Rodriguez J, Dreilinger AD, Alsharabi GM, Rearden A: The signaling adapter protein PINCH is upregulated in the stroma of common cancers, notably at invasion edges. Cancer. 2002, 95: 1387-1395. 10.1002/cncr.10878PubMedCrossRef
212.
Zhao ZR, Zhang ZY, Cui DS, Jiang L, Zhang HJ, Wang MW, Sun XF: PINCH expression in colorectal adenocarcinoma. World J Gastroenterol. 2006, 14, 12: 298-301.
213.
Lieubeau B, Heymann MF, Henry F, Barbieux I, Meflah K, Gregoire M: Immunomodulatory effects of tumor-associated fibroblasts in colorectal-tumor development. Int J Cancer. 1999, 81: 629-636. 10.1002/(SICI)1097-0215(19990517)81:4<629::AID-IJC20>3.0.CO;2-8PubMedCrossRef
214.
Marty C, Langer-Machova Z, Sigrist S, Schott H, Schwendener RA, Ballmer-Hofer K: Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Lett. 2006, 235: 298-308. 10.1016/j.canlet.2005.04.029PubMedCrossRef
215.
Gille J: Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol. 2006, 5: 175-186. 10.1111/j.1600-0625.2006.00400.x.CrossRef
216.
Van Cutsem E: Progress with biological agents in metastatic colorectal cancer leads to many challenges. J Clin Oncol. 2006, 24: 3325-3327. 10.1200/JCO.2006.06.2067PubMedCrossRef
217.
Bovo G, Brivio F, Brenna A, Fumagalli L, Perego P, Brivio O, Uggeri F, Lavorato F, Bratina G: Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma. Pathologica. 1995, 87: 135-138.PubMed
218.
Monden T, Morimoto H, Shimano T, Yagyu T, Murotani M, Nagaoka H, Kawasaki Y, Kobayashi T, Mori T: Use of fibrinogen to enhance the antitumor effect of OK-432. A new approach to immunotherapy for colorectal carcinoma. Cancer. 1992, 69: 636-642. 10.1002/1097-0142(19920201)69:3<636::AID-CNCR2820690306>3.0.CO;2-WPubMedCrossRef
219.
Zucker S, Vacirca J: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004, 23: 101-117. 10.1023/A:1025867130437PubMedCrossRef
220.
Ogata Y, Matono K, Sasatomi T, Ishibashi N, Ohkita A, Mizobe T, Ogo S, Ikeda S, Ozasa H, Shirouzu K: The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother Pharmacol. 2006, 57: 577-583. 10.1007/s00280-005-0081-9PubMedCrossRef
Metadata
Title
Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas
Authors
Xiao-Feng Sun
Hong Zhang
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2006
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-5-43

Other articles of this Issue 1/2006

Molecular Cancer 1/2006 Go to the issue

Research

Myb proteins inhibit fibroblast transformation by v-Rel

Review

Application of cytology and molecular biology in diagnosing premalignant or malignant oral lesions

Research

A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer

Research

Hypoxia-inducible factor-1α polymorphisms and TSC1/2 mutations are complementary in head and neck cancers

Research

Stable low-level expression of p21WAF1/CIP1 in A549 human bronchogenic carcinoma cell line-derived clones down-regulates E2F1 mRNA and restores cell proliferation control

Research

Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits